Latest news with #SimulationsPlus
Yahoo
25-05-2025
- Business
- Yahoo
3 Intriguing Stocks Estimated At Up To 42.7% Below Intrinsic Value
As the United States market grapples with renewed trade tensions and fluctuating indices, investors are keenly observing the impact on economic growth and corporate profits. In such a volatile environment, identifying stocks trading below their intrinsic value can present unique opportunities for those looking to capitalize on potential mispricings. Name Current Price Fair Value (Est) Discount (Est) Berkshire Hills Bancorp (NYSE:BHLB) $25.09 $50.02 49.8% UMH Properties (NYSE:UMH) $16.38 $32.38 49.4% Super Group (SGHC) (NYSE:SGHC) $8.37 $16.54 49.4% Burke & Herbert Financial Services (NasdaqCM:BHRB) $55.59 $108.72 48.9% Advanced Flower Capital (NasdaqGM:AFCG) $4.83 $9.39 48.6% Hims & Hers Health (NYSE:HIMS) $53.52 $106.29 49.6% Finward Bancorp (NasdaqCM:FNWD) $30.00 $59.39 49.5% TXO Partners (NYSE:TXO) $15.30 $29.97 49% ZEEKR Intelligent Technology Holding (NYSE:ZK) $29.40 $57.19 48.6% Agora (NasdaqGS:API) $3.68 $7.25 49.2% Click here to see the full list of 169 stocks from our Undervalued US Stocks Based On Cash Flows screener. Underneath we present a selection of stocks filtered out by our screen. Overview: Simulations Plus, Inc. develops drug discovery and development software that leverages artificial intelligence and machine learning for modeling, simulation, and molecular property prediction globally, with a market cap of $637.52 million. Operations: The company's revenue is derived from two main segments: Services, which generated $32.54 million, and Software, contributing $46.02 million. Estimated Discount To Fair Value: 18.9% Simulations Plus is trading at US$32.49, approximately 18.9% below its estimated fair value of US$40.08, indicating potential undervaluation based on cash flows. Despite a decline in profit margins from 16.3% to 9.2%, the company expects revenue growth between US$90 million and US$93 million for 2025, supported by new product releases like DILIsym 11 and alignment with FDA initiatives to reduce animal testing, potentially driving future earnings growth significantly above market rates. Our expertly prepared growth report on Simulations Plus implies its future financial outlook may be stronger than recent results. Click here and access our complete balance sheet health report to understand the dynamics of Simulations Plus. Overview: Sportradar Group AG, along with its subsidiaries, offers sports data services to the sports betting and media industries across various global regions, with a market cap of approximately $6.97 billion. Operations: The company generates revenue primarily from its Data Processing segment, which amounts to €1.15 billion. Estimated Discount To Fair Value: 32.9% Sportradar Group, trading at $23.71, is valued 32.9% below its estimated fair value of $35.32, highlighting potential undervaluation based on cash flows. The company reported a significant turnaround with net income of €24.21 million in Q1 2025 compared to a loss the previous year and expects revenue growth of at least 15% for fiscal 2025. Despite low forecasted return on equity, earnings are projected to grow significantly faster than the US market average over the next three years. Insights from our recent growth report point to a promising forecast for Sportradar Group's business outlook. Unlock comprehensive insights into our analysis of Sportradar Group stock in this financial health report. Overview: Fiverr International Ltd. operates a global online marketplace and has a market cap of approximately $1.16 billion. Operations: The company's revenue is primarily generated from its Internet Software & Services segment, totaling $405.14 million. Estimated Discount To Fair Value: 42.7% Fiverr International, trading at US$33.15, is considered undervalued with a fair value estimate of US$57.86. The company raised its 2025 revenue guidance to between US$425 million and US$438 million, reflecting growth expectations of 9% to 12%. Earnings are expected to grow significantly at 38.4% annually over the next three years, outpacing the broader market's growth rate. A share repurchase program worth up to $100 million further underscores potential shareholder value enhancement. According our earnings growth report, there's an indication that Fiverr International might be ready to expand. Click to explore a detailed breakdown of our findings in Fiverr International's balance sheet health report. Take a closer look at our Undervalued US Stocks Based On Cash Flows list of 169 companies by clicking here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:SLP NasdaqGS:SRAD and NYSE:FVRR. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
23-05-2025
- Business
- Yahoo
3 Intriguing Stocks Estimated At Up To 42.7% Below Intrinsic Value
As the United States market grapples with renewed trade tensions and fluctuating indices, investors are keenly observing the impact on economic growth and corporate profits. In such a volatile environment, identifying stocks trading below their intrinsic value can present unique opportunities for those looking to capitalize on potential mispricings. Name Current Price Fair Value (Est) Discount (Est) Berkshire Hills Bancorp (NYSE:BHLB) $25.09 $50.02 49.8% UMH Properties (NYSE:UMH) $16.38 $32.38 49.4% Super Group (SGHC) (NYSE:SGHC) $8.37 $16.54 49.4% Burke & Herbert Financial Services (NasdaqCM:BHRB) $55.59 $108.72 48.9% Advanced Flower Capital (NasdaqGM:AFCG) $4.83 $9.39 48.6% Hims & Hers Health (NYSE:HIMS) $53.52 $106.29 49.6% Finward Bancorp (NasdaqCM:FNWD) $30.00 $59.39 49.5% TXO Partners (NYSE:TXO) $15.30 $29.97 49% ZEEKR Intelligent Technology Holding (NYSE:ZK) $29.40 $57.19 48.6% Agora (NasdaqGS:API) $3.68 $7.25 49.2% Click here to see the full list of 169 stocks from our Undervalued US Stocks Based On Cash Flows screener. Underneath we present a selection of stocks filtered out by our screen. Overview: Simulations Plus, Inc. develops drug discovery and development software that leverages artificial intelligence and machine learning for modeling, simulation, and molecular property prediction globally, with a market cap of $637.52 million. Operations: The company's revenue is derived from two main segments: Services, which generated $32.54 million, and Software, contributing $46.02 million. Estimated Discount To Fair Value: 18.9% Simulations Plus is trading at US$32.49, approximately 18.9% below its estimated fair value of US$40.08, indicating potential undervaluation based on cash flows. Despite a decline in profit margins from 16.3% to 9.2%, the company expects revenue growth between US$90 million and US$93 million for 2025, supported by new product releases like DILIsym 11 and alignment with FDA initiatives to reduce animal testing, potentially driving future earnings growth significantly above market rates. Our expertly prepared growth report on Simulations Plus implies its future financial outlook may be stronger than recent results. Click here and access our complete balance sheet health report to understand the dynamics of Simulations Plus. Overview: Sportradar Group AG, along with its subsidiaries, offers sports data services to the sports betting and media industries across various global regions, with a market cap of approximately $6.97 billion. Operations: The company generates revenue primarily from its Data Processing segment, which amounts to €1.15 billion. Estimated Discount To Fair Value: 32.9% Sportradar Group, trading at $23.71, is valued 32.9% below its estimated fair value of $35.32, highlighting potential undervaluation based on cash flows. The company reported a significant turnaround with net income of €24.21 million in Q1 2025 compared to a loss the previous year and expects revenue growth of at least 15% for fiscal 2025. Despite low forecasted return on equity, earnings are projected to grow significantly faster than the US market average over the next three years. Insights from our recent growth report point to a promising forecast for Sportradar Group's business outlook. Unlock comprehensive insights into our analysis of Sportradar Group stock in this financial health report. Overview: Fiverr International Ltd. operates a global online marketplace and has a market cap of approximately $1.16 billion. Operations: The company's revenue is primarily generated from its Internet Software & Services segment, totaling $405.14 million. Estimated Discount To Fair Value: 42.7% Fiverr International, trading at US$33.15, is considered undervalued with a fair value estimate of US$57.86. The company raised its 2025 revenue guidance to between US$425 million and US$438 million, reflecting growth expectations of 9% to 12%. Earnings are expected to grow significantly at 38.4% annually over the next three years, outpacing the broader market's growth rate. A share repurchase program worth up to $100 million further underscores potential shareholder value enhancement. According our earnings growth report, there's an indication that Fiverr International might be ready to expand. Click to explore a detailed breakdown of our findings in Fiverr International's balance sheet health report. Take a closer look at our Undervalued US Stocks Based On Cash Flows list of 169 companies by clicking here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:SLP NasdaqGS:SRAD and NYSE:FVRR. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
15-05-2025
- Health
- Yahoo
Simulations Plus Releases DILIsym® 11
Newest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations RESEARCH TRIANGLE PARK, N.C., May 15, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platform. "Advancing toxicology research and improving the prediction of drug-induced liver injury (DILI) are essential to developing safer treatments," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "DILIsym continues to set the standard by enabling researchers to assess potential liver safety risks, as well as explore dosing strategies that optimize patient safety. We are proud to support innovation that directly impacts patient health and drug development success." "The addition of pediatric representation is an important milestone in predictive toxicology," said Dr. Scott Q. Siler, Chief Scientific Officer of QSP Solutions of Simulations Plus. "By advancing the evaluation of potential liver safety risks in children, DILIsym 11 will support the development of safer and more effective therapies for children across the globe. We are proud of our role in developing leading-edge modeling tools that help bring better treatment options to vulnerable patient populations." DILIsym is a software platform designed to predict potential DILI hazards and provide insight into the mechanisms responsible for observed DILI responses. It is the most widely used QST modeling software for DILI prediction and is utilized as a source of QST modeling-based data assessed by the U.S. Food and Drug Administration's (FDA) DILI team. DILIsym 11 offers new pediatric representation for exploratory predictions regarding liver safety to children, and a new T-cell model that allows for better understanding of putative contributions of CD8+ T-cell mediated hepatocellular injury. It also includes improved representation of bile acid and cholestatic liver injury, updated antioxidant adaptation mechanisms, and more. Learn more about DILIsym 11 and request your evaluation license. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will," "can," "believe," "expect," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on Contacts Financial Profiles Lisa Fortuna310-622-8251slp@
Associated Press
15-05-2025
- Business
- Associated Press
Simulations Plus Releases DILIsym® 11
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 15, 2025-- Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym ® 11, the latest version of its flagship quantitative systems toxicology (QST) platform. 'Advancing toxicology research and improving the prediction of drug-induced liver injury (DILI) are essential to developing safer treatments,' said Shawn O'Connor, Chief Executive Officer of Simulations Plus. 'DILIsym continues to set the standard by enabling researchers to assess potential liver safety risks, as well as explore dosing strategies that optimize patient safety. We are proud to support innovation that directly impacts patient health and drug development success.' 'The addition of pediatric representation is an important milestone in predictive toxicology,' said Dr. Scott Q. Siler, Chief Scientific Officer of QSP Solutions of Simulations Plus. 'By advancing the evaluation of potential liver safety risks in children, DILIsym 11 will support the development of safer and more effective therapies for children across the globe. We are proud of our role in developing leading-edge modeling tools that help bring better treatment options to vulnerable patient populations.' DILIsym is a software platform designed to predict potential DILI hazards and provide insight into the mechanisms responsible for observed DILI responses. It is the most widely used QST modeling software for DILI prediction and is utilized as a source of QST modeling-based data assessed by the U.S. Food and Drug Administration's (FDA) DILI team. DILIsym 11 offers new pediatric representation for exploratory predictions regarding liver safety to children, and a new T-cell model that allows for better understanding of putative contributions of CD8+ T-cell mediated hepatocellular injury. It also includes improved representation of bile acid and cholestatic liver injury, updated antioxidant adaptation mechanisms, and more. Learn more about DILIsym 11 and request your evaluation license. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will,' 'can,' 'believe,' 'expect,' 'anticipate' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on CONTACT: Financial Profiles Lisa Fortuna 310-622-8251 [email protected] KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA INDUSTRY KEYWORD: FDA HEALTH TECHNOLOGY ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) TECHNOLOGY CONSULTING PHARMACEUTICAL PROFESSIONAL SERVICES ARTIFICIAL INTELLIGENCE CHILDREN CLINICAL TRIALS BIOTECHNOLOGY SCIENCE SOFTWARE CONSUMER RESEARCH HEALTH SOURCE: Simulations Plus, Inc. Copyright Business Wire 2025. PUB: 05/15/2025 07:50 AM/DISC: 05/15/2025 07:49 AM
Business Wire
15-05-2025
- Health
- Business Wire
Simulations Plus Releases DILIsym ® 11
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym ® 11, the latest version of its flagship quantitative systems toxicology (QST) platform. 'Advancing toxicology research and improving the prediction of drug-induced liver injury (DILI) are essential to developing safer treatments,' said Shawn O'Connor, Chief Executive Officer of Simulations Plus. 'DILIsym continues to set the standard by enabling researchers to assess potential liver safety risks, as well as explore dosing strategies that optimize patient safety. We are proud to support innovation that directly impacts patient health and drug development success.' 'The addition of pediatric representation is an important milestone in predictive toxicology,' said Dr. Scott Q. Siler, Chief Scientific Officer of QSP Solutions of Simulations Plus. 'By advancing the evaluation of potential liver safety risks in children, DILIsym 11 will support the development of safer and more effective therapies for children across the globe. We are proud of our role in developing leading-edge modeling tools that help bring better treatment options to vulnerable patient populations.' DILIsym is a software platform designed to predict potential DILI hazards and provide insight into the mechanisms responsible for observed DILI responses. It is the most widely used QST modeling software for DILI prediction and is utilized as a source of QST modeling-based data assessed by the U.S. Food and Drug Administration's (FDA) DILI team. DILIsym 11 offers new pediatric representation for exploratory predictions regarding liver safety to children, and a new T-cell model that allows for better understanding of putative contributions of CD8+ T-cell mediated hepatocellular injury. It also includes improved representation of bile acid and cholestatic liver injury, updated antioxidant adaptation mechanisms, and more. Learn more about DILIsym 11 and request your evaluation license. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will,' 'can,' 'believe,' 'expect,' 'anticipate' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
